PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
A systematic review of randomized double-blind controlled trials indicated that P. tenuifolia is associated with positive cognitive enhancing outcomes [PMID:22303969]. A meta-analysis evaluated the clinical efficacy of P. tenuifolia paired with Acorus tatarinowii for AD treatment [PMID:38283842].
Extract alleviated LPS-induced ALI in rats via TLR4/NF-κB pathway and NLRP3 inflammasome suppression [PMID:38972239].
Root extract attenuated brain infarction and neurological deficits in tMCAO rats by inhibiting HMGB1 [PMID:39476989].
Extract delayed NAFLD progression in rats via the COX2 and PERK-eIF2α-ATF4 pathway [PMID:40575786].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 38972239 (2024) — Polygala tenuifolia willd. Extract alleviates LPS-induced acute lung injury in rats via TLR4/NF-κB pathway and NLRP3 inflammasome suppression. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 2.PMID: 22414105 (2012) — Nature against depression. · Current medicinal chemistry
- 3.PMID: 22303969 (2012) — Chinese herbs for dementia diseases. · Mini reviews in medicinal chemistry
- 4.PMID: 32429787 (2020) — Polygala tenuifolia: a source for anti-Alzheimer's disease drugs. · Pharmaceutical biology
- 5.PMID: 28807163 (2017) — Effect of Chinese Herbal Medicine on Alzheimer's Disease.